EA201892548A1 - Антитела к альфа-синуклеину и их применение - Google Patents

Антитела к альфа-синуклеину и их применение

Info

Publication number
EA201892548A1
EA201892548A1 EA201892548A EA201892548A EA201892548A1 EA 201892548 A1 EA201892548 A1 EA 201892548A1 EA 201892548 A EA201892548 A EA 201892548A EA 201892548 A EA201892548 A EA 201892548A EA 201892548 A1 EA201892548 A1 EA 201892548A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
synuclein
methods
sinuculine
alpha
Prior art date
Application number
EA201892548A
Other languages
English (en)
Other versions
EA038358B1 (ru
Inventor
Майкл Перкинтон
Дарен Шофилд
Лоррейн Ирвинг
Джордж Том
Original Assignee
Медиммун Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медиммун Лимитед filed Critical Медиммун Лимитед
Publication of EA201892548A1 publication Critical patent/EA201892548A1/ru
Publication of EA038358B1 publication Critical patent/EA038358B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Согласно изобретению предложены антитела, специфично связывающиеся с человеческим α-синуклеином с высокой аффинностью и уменьшающие распространение α-синуклеина in vivo, рекомбинантные полипептиды, содержащие указанные антитела или их антиген-связывающие фрагменты, и способы получения таких полипептидов, а также композиции и способы получения антител к α-синуклеину и способы применения антител к α-синуклеину для лечения заболеваний центральной нервной системы, в частности α-синуклеинопатий.
EA201892548A 2016-06-02 2017-06-01 Антитела к альфа-синуклеину и их применение EA038358B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662344746P 2016-06-02 2016-06-02
PCT/EP2017/063406 WO2017207739A1 (en) 2016-06-02 2017-06-01 Antibodies to alpha-synuclein and uses thereof

Publications (2)

Publication Number Publication Date
EA201892548A1 true EA201892548A1 (ru) 2019-06-28
EA038358B1 EA038358B1 (ru) 2021-08-13

Family

ID=59021492

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202191380A EA202191380A1 (ru) 2016-06-02 2017-06-01 Антитела к альфа-синуклеину и их применение
EA201892548A EA038358B1 (ru) 2016-06-02 2017-06-01 Антитела к альфа-синуклеину и их применение

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA202191380A EA202191380A1 (ru) 2016-06-02 2017-06-01 Антитела к альфа-синуклеину и их применение

Country Status (36)

Country Link
US (4) US10160800B2 (ru)
EP (2) EP4000632A1 (ru)
JP (2) JP7078552B2 (ru)
KR (1) KR102499438B1 (ru)
CN (2) CN116120445A (ru)
AR (1) AR108663A1 (ru)
AU (2) AU2017272804B2 (ru)
BR (1) BR112018074978A2 (ru)
CA (1) CA3025987A1 (ru)
CL (1) CL2018003438A1 (ru)
CO (1) CO2018014010A2 (ru)
CY (1) CY1124896T1 (ru)
DK (1) DK3463435T3 (ru)
EA (2) EA202191380A1 (ru)
EC (1) ECSP18096095A (ru)
ES (1) ES2903402T3 (ru)
GE (1) GEP20217253B (ru)
HR (1) HRP20211935T1 (ru)
HU (1) HUE057214T2 (ru)
IL (1) IL263243A (ru)
LT (1) LT3463435T (ru)
MA (1) MA45125B1 (ru)
MD (1) MD3463435T2 (ru)
MX (1) MX2018014456A (ru)
MY (1) MY188183A (ru)
PE (1) PE20190440A1 (ru)
PH (1) PH12018502538A1 (ru)
PL (1) PL3463435T3 (ru)
PT (1) PT3463435T (ru)
RS (1) RS62682B1 (ru)
SG (1) SG11201810420YA (ru)
SI (1) SI3463435T1 (ru)
TW (2) TW202309093A (ru)
UA (1) UA124733C2 (ru)
WO (1) WO2017207739A1 (ru)
ZA (1) ZA201808582B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
WO2018091444A1 (en) 2016-11-15 2018-05-24 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
US11325968B2 (en) 2016-12-16 2022-05-10 H. Lundbeck A/S Alpha-synuclein antibodies
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
WO2018151821A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
EP3867270A1 (en) * 2018-10-19 2021-08-25 Janssen Vaccines & Prevention B.V. Anti-synuclein antibodies
TWI734279B (zh) * 2018-12-14 2021-07-21 美商美國禮來大藥廠 抗α-突觸核蛋白抗體及其用途
EP3956027A1 (en) 2019-04-18 2022-02-23 AC Immune SA Novel molecules for therapy and diagnosis
CN110172098B (zh) * 2019-05-27 2023-03-10 长春工业大学 抗α-突触核蛋白的单克隆抗体及其应用
WO2021055881A1 (en) 2019-09-20 2021-03-25 Denali Therapeutics Inc. Anti-alpha-synuclein antibodies and methods of use thereof
KR102239512B1 (ko) * 2020-09-10 2021-04-12 서울대학교산학협력단 다중기능성 마이크로캡슐 조성물 및 그 제조방법
EP4229082A1 (en) 2020-10-16 2023-08-23 AC Immune SA Antibodies binding to alpha-synuclein for therapy and diagnosis
CN112920274A (zh) * 2021-03-17 2021-06-08 江苏贝格尔生物医药有限公司 一种检测alpha-synuclein蛋白的鼠单克隆抗体及其应用
CN113912716B (zh) * 2021-12-15 2022-03-01 北京凯祥弘康生物科技有限公司 针对α-突触核蛋白抗原的抗体及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066754A1 (en) 2000-03-03 2001-09-13 Cambridge Antibody Technology Limited Human antibodies against eotaxin and their use
CA2441903C (en) 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
WO2002003911A2 (en) 2000-07-07 2002-01-17 Lars Lannfelt Prevention and treatment of alzheimer's disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
HUE034320T2 (en) 2003-05-19 2018-02-28 Prothena Biosciences Ltd Truncated fragments of alpha-synuclein in lewy-body disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
EA013752B1 (ru) 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
WO2007036021A1 (en) 2005-09-27 2007-04-05 National Research Council Of Canada Blood-brain barrier epitopes and uses thereof
PL2118300T3 (pl) 2007-02-23 2015-11-30 Prothena Biosciences Ltd Zapobieganie i leczenie synukleinopatii i amyloidozy
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
JP4934074B2 (ja) 2007-03-07 2012-05-16 株式会社アルファ スイッチ固定構造
WO2009133521A2 (en) 2008-04-29 2009-11-05 Bioartic Neuroscience Ab Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders
EP2949666B1 (en) 2008-12-19 2018-12-19 Biogen International Neuroscience GmbH Human anti-alpha-synuclein antibodies
JP4654348B1 (ja) 2010-02-23 2011-03-16 多摩川精機株式会社 検出装置用巻線の正弦波巻線方法
JP5894939B2 (ja) * 2010-02-26 2016-03-30 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用
AU2012272790B2 (en) 2011-06-23 2016-10-06 Biogen International Neuroscience Gmbh Anti-alpha synuclein binding molecules
EP3378535B1 (en) 2011-10-28 2023-01-04 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
KR102358311B1 (ko) 2013-11-21 2022-02-08 에프. 호프만-라 로슈 아게 항-알파-시누클레인 항체 및 사용 방법
SI3218406T1 (sl) 2014-11-10 2021-08-31 Medimmune Limited Vezavne molekule specifične za CD73 in njihove uporabe

Also Published As

Publication number Publication date
EA038358B1 (ru) 2021-08-13
UA124733C2 (uk) 2021-11-10
TWI765890B (zh) 2022-06-01
DK3463435T3 (da) 2021-11-22
PL3463435T3 (pl) 2022-02-14
SG11201810420YA (en) 2018-12-28
CN116120445A (zh) 2023-05-16
LT3463435T (lt) 2021-12-27
AR108663A1 (es) 2018-09-12
PT3463435T (pt) 2021-11-22
MA45125B1 (fr) 2021-11-30
WO2017207739A1 (en) 2017-12-07
KR102499438B1 (ko) 2023-02-14
BR112018074978A2 (pt) 2019-03-12
ECSP18096095A (es) 2019-01-31
TW202309093A (zh) 2023-03-01
KR20190013923A (ko) 2019-02-11
IL263243A (en) 2018-12-31
ES2903402T3 (es) 2022-04-01
MD3463435T2 (ro) 2022-03-31
US11560424B2 (en) 2023-01-24
EA202191380A1 (ru) 2021-08-26
MX2018014456A (es) 2019-08-12
HUE057214T2 (hu) 2022-04-28
GEP20217253B (en) 2021-05-13
CO2018014010A2 (es) 2019-01-18
US20180002411A1 (en) 2018-01-04
RS62682B1 (sr) 2021-12-31
PH12018502538A1 (en) 2019-04-08
JP2022110117A (ja) 2022-07-28
JP7078552B2 (ja) 2022-05-31
PE20190440A1 (es) 2019-03-27
JP2019527194A (ja) 2019-09-26
EP3463435B1 (en) 2021-10-13
US10160800B2 (en) 2018-12-25
CN109475616B (zh) 2022-10-18
TW201802119A (zh) 2018-01-16
HRP20211935T1 (hr) 2022-03-18
AU2017272804B2 (en) 2023-11-23
US10889639B2 (en) 2021-01-12
CA3025987A1 (en) 2017-12-07
MA45125A (fr) 2021-06-02
US20210179698A1 (en) 2021-06-17
ZA201808582B (en) 2021-08-25
CN109475616A (zh) 2019-03-15
AU2017272804A1 (en) 2018-12-13
US20230331830A1 (en) 2023-10-19
US20190276522A1 (en) 2019-09-12
AU2024200601A1 (en) 2024-04-18
CY1124896T1 (el) 2023-01-05
CL2018003438A1 (es) 2019-03-22
MY188183A (en) 2021-11-24
EP4000632A1 (en) 2022-05-25
SI3463435T1 (sl) 2022-02-28
EP3463435A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
EA201892548A1 (ru) Антитела к альфа-синуклеину и их применение
EA201992131A1 (ru) Высокоаффинные специфичные к mage-a1 tcr и их применение
CL2019002566A1 (es) Anticuerpos anti-phf-tau y usos de estos.
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
EA201590085A1 (ru) Антитела анти-egfr и их применение
MD4716C1 (ru) Антитела анти-LAG3 и антигенсвязывающие фрагменты
EA201492149A1 (ru) St2-антигенсвязывающие белки
PH12016500943A1 (en) Aplnr modulatros and uses thereof
MX2023000738A (es) Proteinas de union a antigeno que activan el receptor de leptina.
PH12017501522A1 (en) Antibodies to tau and uses thereof
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
PH12017502020A1 (en) Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
EA202090401A1 (ru) Анти-tim-3 антитела и их применение
EA202190807A1 (ru) Антитела к синуклеину
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EA202191656A1 (ru) Анти-il-36 антитела и способы их применения
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
PH12017500332A1 (en) Antigen binding proteins that bind cxcr3
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
WO2016040767A3 (en) Chrdl-1 epitopes and antibodies
EA202192254A1 (ru) Fcmr-связывающие молекулы и их применение
EA201992057A1 (ru) Персонализированная платформа для идентификации иммуногенного пептида